<DOC>
	<DOCNO>NCT01335685</DOCNO>
	<brief_summary>This phase 1/2 , multicenter , 2-arm , open-label study use oral formulation IXAZOMIB add standard melphalan prednisone ( MP ) treatment . Both phase study include patient newly diagnose multiple myeloma ineligible high-dose therapy plus stem cell transplantation age ( â‰¥65 year age ) coexist condition standard MP treatment indicate . Note : Phase 2 trial randomize .</brief_summary>
	<brief_title>Study Oral IXAZOMIB Combination With Melphalan Prednisone Patients With Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Ixazomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>Male female patient standard melphalan prednisone ( MP ) treatment indicated candidate highdose therapy plus stem cell transplantation ( HDTSCT ) 1 follow reason : patient 65 year age old OR patient le 65 year age significant comorbid condition ( ) likely negative impact tolerability HDTSCT Symptomatic multiple myeloma asymptomatic myeloma myelomarelated organ damage diagnose accord standard criterion Measurable disease specify study protocol Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Must adequate hematologic , liver , renal function Female patient post menopausal , surgically sterile , agree practice 2 effective method contraception agree abstain heterosexual intercourse Male patient agree practice effective barrier contraception agree abstain heterosexual intercourse Voluntary write consent Exclusion Criteria Peripheral neuropathy great equal Grade 2 Female patient lactate pregnant Major surgery radiotherapy within 14 day first dose study drug Uncontrolled infection require systematic antibiotic Diarrhea ( &gt; Grade 1 ) Prior systemic therapy multiple myeloma , include investigational drug ( prior treatment corticosteroid localize radiation therapy dose disqualify patient ) Central nervous system involvement Cardiac status describe protocol Known gastrointestinal condition procedure could interfere swallow oral absorption tolerance IXAZOMIB Diagnosis smolder multiple myeloma , Waldenstrom 's macroglobulinemia , POEMS syndrome , plasma cell leukemia , primary amyloidosis , myelodysplastic syndrome , myeloproliferative syndrome Known human immunodeficiency virus ( HIV ) positive , hepatitis B surface antigenpositive status , know suspect active hepatitis C infection Diagnosed treat another malignancy within 2 year first dose previously diagnose another malignancy evidence residual disease exception nonmelanoma skin cancer completely resect carcinoma situ Serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>